Robert W. Baird Reaffirms “Outperform” Rating for Agilent Technologies (NYSE:A)

Robert W. Baird reaffirmed their outperform rating on shares of Agilent Technologies (NYSE:A) in a research report report published on Thursday morning, The Fly reports. They currently have a $82.00 price target on the medical research company’s stock, up from their prior price target of $79.00.

Several other research firms have also issued reports on A. Bank of America lowered Agilent Technologies from a buy rating to a neutral rating and set a $76.00 target price for the company. in a research report on Tuesday, July 16th. Wolfe Research assumed coverage on Agilent Technologies in a research report on Thursday, May 30th. They set a peer perform rating for the company. Deutsche Bank cut their price objective on Agilent Technologies from $90.00 to $85.00 and set a buy rating on the stock in a report on Wednesday, May 15th. Piper Jaffray Companies lifted their price objective on Agilent Technologies from $83.00 to $86.00 and gave the company an overweight rating in a report on Thursday. Finally, ValuEngine cut Agilent Technologies from a buy rating to a hold rating in a report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $84.15.

Agilent Technologies stock opened at $71.08 on Thursday. The firm has a market capitalization of $21.99 billion, a P/E ratio of 22.89, a PEG ratio of 1.92 and a beta of 1.41. Agilent Technologies has a 1 year low of $61.01 and a 1 year high of $82.27. The business has a 50-day moving average of $70.77 and a 200-day moving average of $74.61. The company has a current ratio of 2.13, a quick ratio of 2.82 and a debt-to-equity ratio of 0.27.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 14th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.04. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.24 billion. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.67 EPS. Research analysts anticipate that Agilent Technologies will post 3.08 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd were issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend was Monday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

Several large investors have recently added to or reduced their stakes in A. Magnetar Financial LLC bought a new stake in Agilent Technologies in the 2nd quarter valued at approximately $4,686,000. Orbimed Advisors LLC lifted its stake in Agilent Technologies by 11.8% in the 2nd quarter. Orbimed Advisors LLC now owns 893,200 shares of the medical research company’s stock valued at $66,695,000 after acquiring an additional 94,500 shares in the last quarter. Prudential PLC lifted its stake in Agilent Technologies by 7.3% in the 2nd quarter. Prudential PLC now owns 25,031 shares of the medical research company’s stock valued at $1,877,000 after acquiring an additional 1,710 shares in the last quarter. WealthStone Inc. bought a new stake in Agilent Technologies in the 2nd quarter valued at approximately $31,000. Finally, HM Payson & Co. bought a new stake in Agilent Technologies in the 2nd quarter valued at approximately $162,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: What is a CD ladder?

The Fly

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.